Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 2/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ACP3 | P15309 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 5/20 | 0.40 |
| ▸ | PGK1 | P00558 | 1/20 | 0.40 |
| ▸ | PGK2 | P07205 | 1/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14339435 | 0.83 | KIF11 (0.47) | HTR2AHTR2BHTR2CKIF11TAAR1 | |
| SCHEMBL6377331 | 0.83 | HTR2A (0.46) | HTR2AHTR2BHTR2CKIF11TAAR1 | |
| SCHEMBL16105797 | 0.83 | HTR2A (0.46) | HTR2AHTR2BHTR2CKIF11TAAR1 | |
| SCHEMBL46757 | 0.83 | HTR2A (0.63) | HTR2AHTR2BHTR2CTAAR1SIGMAR1 | |
| SCHEMBL10233507 | 0.82 | HTR2A (0.44) | HTR2AHTR2BHTR2CKIF11TAAR1 | |
| Ammonia Solution, Strong SCHEMBL266843 | 0.81 | HTR2A (0.61) | HTR2AHTR2BHTR2CTAAR1SIGMAR1 | |
| SCHEMBL20811436 | 0.81 | HTR2A (0.47) | HTR2AHTR2BHTR2CKIF11TAAR1 | |
| SCHEMBL17805427 | 0.81 | HTR2A (0.47) | HTR2AHTR2BHTR2CKIF11TAAR1 | |
| SCHEMBL128188 | 0.80 | RORC (0.50) | HTR2AHTR2BHTR2C | |
| SCHEMBL24961819 | 0.79 | PGK1 (0.44) | HTR2AHTR2BHTR2CKIF11TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3292101-B1 | TRICYCLIC SULFONES AS ROR-GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-3541786-B1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-05 | — | — | EP | disclosed |
| US-7169955-B2 | Perfluoroisopropylbenzene derivative | NIHON NOHYAKU CO., LTD. (JP) | 2007-01-30 | — | — | US | disclosed |
| US-20050113567-A1 | Perfluoroisopropylbenzene derivative | NIHON NOHYAKU CO., LTD. (JP) | 2005-05-26 | — | — | US | disclosed |
| US-20030187233-A1 | PERFLUOROISOPROPYBENZENE DERIVATIVE | NIHON NOHYAKU CO., LTD. (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1253128-A1 | PERFLUOROISOPROPYLBENZENE DERIVATIVES | Nihon Nohyaku Co., Ltd. (JP) | 2002-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187233-A1 | PERFLUOROISOPROPYBENZENE DERIVATIVE | AFF1, CBR1, RER1 | HTR2A 1190/4885HTR2B 1233/4885HTR2C 884/4885 |
| US-20050113567-A1 | Perfluoroisopropylbenzene derivative | FFAR3, CBR3, HCAR3 | HTR2A 864/4885HTR2B 458/4885HTR2C 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.